

## Analgesics Following Mandibular Third Molar Surgery

\*Nazar. M.N., Puthiriraj. V

*Saveetha University, No. 62, Poonamallee High Road, Velappanchavadi, Chennai, Tamil Nadu, India.*

*Available online: 12<sup>th</sup> November 2013*

---

### ABSTRACT

Surgical extraction of third molars is a commonly performed clinical procedure and is usually associated with postoperative pain, swelling and trismus. Several studies have compared the drugs used to control postoperative pain after surgical removal of third molars. The adverse effects of the wisdom tooth surgery on the quality of life has been reported to show a three-fold increase in patients who experience pain, swelling and trismus alone or in combinations; compared to those who were asymptomatic. This article reviews the various analgesics used in third molar surgery and emphasizes the necessity for better pain, swelling and trismus control in patients who undergo this procedure.

**Key Words:** Analgesic; Impacted Third molar; Inflammation; Non-steroidal anti-inflammatory drugs; Opioids.

---

### INTRODUCTION

The surgical removal of impacted mandibular third molars is one of the most commonly performed dento-alveolar procedures in oral and maxillofacial surgery and is associated with varying degrees of postoperative discomfort. Pain, trismus, and swelling are the most common postoperative complaints, and these influence a patient's quality of life in the days after surgery<sup>1</sup>. It is generally accepted that pain following third molar surgery reaches moderate to severe intensity within the first 5 hour after surgery<sup>2,3</sup>. However, there are studies showing that the postoperative pain reaches its peak intensity during the first 8 hours after the surgery<sup>4</sup>.

The removal of the impacted third molar and the resultant tissue and cellular destruction brings about the release and production of several biochemical mediators involved in the pain process, in particular, histamine, bradykinin and the prostaglandins. Histamine and bradykinin have similar functions. Both cause sensitisation of free nerve endings and similarly, both are involved in oedema formation. However, both substances have short half- lives and therefore the major role of these substances occurs in the early stages after injury. There is a wide armamentarium of analgesics available for clinicians to manage pain and other post-operative sequelae. The problem of dental pain can be tackled using peripherally acting or centrally acting drugs.

One of the most significant advances in maxillofacial surgery over the past 10 year has been in the pharmacological management of patients with acute postoperative pain. The most prevalent methods include administration of: Non-steroidal anti-inflammatory drugs (NSAIDs)<sup>5</sup>, which prevent peripheral sensitization by reducing prostaglandin synthesis at the site of surgery; regional anaesthetics<sup>6</sup>, which block afferent nociceptive impulses prior to incision; opioids<sup>7,8</sup>, which modulate afferent input by blocking the postsynaptic receptors and

decreasing neurotransmitter release or by activating inhibitory pathways; and NMDA-receptor antagonists<sup>9</sup>, which inhibit activation of N-methyl-D-aspartate (NMDA) receptors in the human spinal cord, thus preventing the main mechanism of central sensitization.

The more prolonged periods of pain and inflammation appear to be integrally involved with the formation and function of the prostaglandins, which are a group of biologically active fatty acids derived from arachidonic acid and linoleic acid. Trauma, heat, anoxia or any stimulus which will result in deformation of the cell membrane or activation of lipolysis will elicit hydrolysis of phospholipids and triglycerides which enter the cyclooxygenase or lipoxygenase pathways to release the free fatty acid precursors of prostaglandins. It is possible therefore, that lipoxygenase products, as well as cyclooxygenase products may contribute to the development of pain and oedema in the inflammatory response.

Routes of administration: Different routes have been tried for the administration of analgesics such as topical<sup>10</sup>, oral<sup>11</sup>, sublingual<sup>11,12</sup>, intramuscular<sup>8</sup>, intravenous<sup>13</sup>, intranasal<sup>14,15</sup>.

Intranasal administration of medications is convenient and non-invasive. The drug may penetrate the blood-brain barrier and reach the central nervous system directly<sup>16</sup>. Also, because of the high vascularity of the subepithelial surface of the nasal cavity, drugs may access the venous blood of the systemic circulation, which can avoid first-pass metabolism in the liver<sup>17</sup>.

Timing of the administration of drug: Drugs have been tried pre-operatively and post-operatively. NSAIDs, when administered pre-operatively, seem to reach effective anti-inflammatory levels in tissues before surgical trauma, and they thereby reduce formation in the postoperative phase<sup>18</sup>. Many anesthetists have in the past avoided preoperative administration of NSAIDs because these drugs sometimes

require oral intake before anesthesia and operation, however with the advent of Intravenous drugs it is possible for pre-operative administration even before general anesthesia administration.

**Non-steroidal anti-inflammatory drugs:** There are 2 possible mechanisms for the efficacy of NSAIDs when administered prior to surgical trauma. The first may simply be a pharmacokinetic advantage. By administering the NSAIDs prior to pain onset, drug absorption would have begun and therapeutic blood level will be present at the time of pain onset. Second, the presence of a cyclooxygenase inhibitor at the surgical site may limit the production of prostaglandins and prostacyclins associated with hyperalgesia<sup>19,20</sup>. The reduction of biosynthesis of prostaglandins by inhibition of the cyclo-oxygenase enzyme system is considered an important mechanism of action of NSAIDs. When administered preoperatively, NSAIDs have been shown to be particularly effective in combating postoperative pain and edema<sup>20,21</sup>.

The inhibition of COX-1 in platelets by conventional NSAIDs results in modulation of platelet function leading to prolonged bleeding<sup>22</sup>. With NSAID therapy, dose-dependent water and sodium retention manifested by peripheral edema, elevation in blood pressure, and rarely congestive heart failure are thought to follow the inhibition of PGE<sub>2</sub> synthesis<sup>23</sup>.

#### Indications

- Rheumatic disorders: e.g. ankylosing spondylitis, osteoarthritis, and rheumatoid arthritis including juvenile rheumatoid arthritis, painful syndromes of the vertebral column, nonarticular rheumatism.
- Painful post-operative inflammation and swelling (including dental and orthopedic procedures).
- Painful or inflammatory gynaecological conditions e.g. primary dysmenorrhoea.
- In keeping with general therapeutic principles, the underlying disease should be treated with basic therapy, as appropriate. Diclofenac provides symptomatic relief but has not been shown to halt or reverse the underlying disease process. Fever alone is not an indication.

#### Contraindications

- Gastric or intestinal ulcer.
- Hypersensitivity.
- Patients with haemorrhagic diathesis.
- Patients in who attacks of asthma, urticaria or active rhinitis are precipitated by acetylsalicylic acid or other agents, which inhibit prostaglandin-synthetase activity.

The side effects associated with the use of NSAIDs are numerous, but primarily they are related to gastrointestinal (GI), hematologic, and renal disorders, as well as the propensity to cause skin and mucosal reactions<sup>24</sup>.

**Paracetamol:** It raises pain threshold, but has weak peripheral anti-inflammatory component. Its a good and promptly acting antipyretic. It has negligible anti-inflammatory action. It is a poor inhibitor of PG synthesis in peripheral tissues, but more active on COX in the brain. One explanation offered for the discrepancy between its analgesic-antipyretic and anti-inflammatory actions is its inability to inhibit COX in the presence of peroxides which are generated at sites of

inflammation, but are not present in brain. The ability of paracetamol to inhibit COX-3 (an isoenzyme so far located in dog brain) could also account for its analgesic-antipyretic action.

**Adverse effects:** In isolated antipyretic doses paracetamol is safe and well tolerated. Nausea and rashes occur occasionally. Analgesic nephropathy occurs after years of heavy ingestion of analgesics. Pathological lesions are papillary necrosis, tubular atrophy followed by renal fibrosis. Urine concentrating ability is lost and the kidneys shrink.

Paracetamol in combination with other NSAIDs have been shown to produce good pain relief in dental pain models<sup>25</sup>.  
**Aspirin**

**Dosage:** In general, for adults, doses are taken four times a day for fever or arthritis, with doses near the maximal daily dose used historically for the treatment of rheumatic fever. For the prevention of myocardial infarction in someone with documented or suspected coronary artery disease, much lower doses are taken once daily.

#### Pharmacological actions

- Analgesics (prevention of prostaglandin mediated sensitization of nerve endings, obtunding of peripheral pain receptors)
- Antipyretics (reset hypothalamic thermostat thus increases heat loss)
- Antiinflammatory (suppresses pain, tenderness, swelling, vasodilatation and leucocyte infiltrations)

Mechanism of action is by irreversible inactivation of cyclooxygenase (COX) enzyme.

**Adverse effects:** Peptic ulcer, epigastric distress, nausea, vomiting, hypersensitivity

#### Propionic acid derivatives

**Dosage:** Ibuprofen has a dose-dependent duration of action of around four to eight hours, which is longer than suggested by its short half-life. Onset of analgesia (time to effect) is 24.5 minutes using liquigel format orally. The recommended dose varies with body mass and indication. A dose of 400 mg per dose and 1200 mg per day is considered the maximum amount for over-the-counter use, although, under medical direction, the maximum amount for adults is 800 mg per dose or 3200 mg per day based on an individual's response and tolerance.

**Pharmacological action:** Inhibit protein synthesis- Inhibit platelet aggregation reversibly and cause short lasting prolongation of bleeding time.

**Adverse effect:** Common adverse effects include: nausea, dyspepsia, gastrointestinal ulceration/bleeding, raised liver enzymes, diarrhea, constipation, epistaxis, headache, dizziness, rash, salt and fluid retention, and hypertension. Infrequent adverse effects include: ulceration of esophagus, heart failure, hyperkalemia, renal impairment, confusion, and bronchospasm. Ibuprofen can exacerbate asthma, sometimes fatally.

Ziccardi et al compared the efficacy and safety of a single dose of ibuprofen 200 mg/hydrocodone 7.5 mg with acetaminophen 300 mg/codeine 30 mg, and placebo in the management of postoperative dental pain after surgical

extraction of mandibular third molar and showed that Ibuprofen with hydrocodone was found to be effective<sup>26</sup>, however other studies have shown that Ibuprofen offered satisfactory control of pain for only 65% of patients who underwent routine dento-alveolar surgery<sup>27</sup>. Barden et al in a randomised placebo-controlled trial compared aspirin, ibuprofen and paracetamol and concluded that no major difference is likely<sup>1</sup>.

Kaczmarzyk et al in a prospective double blind randomised double blinded clinical trial examined whether ketoprofen administered 60 min before surgical extraction of the lower wisdom teeth provides effective postsurgical analgesia compared with ketoprofen administered 60 min after surgery or placebo and it was found that Ketoprofen administered after third molar surgery provides more effective pain control than ketoprofen administered before the surgery or placebo<sup>28</sup>

Aryl-acetic acid derivatives

Dosage: Diclofenac Potassium: 50 mg orally 3 times a day. In some patients an initial dose of 100 mg of diclofenac potassium, followed by 50 mg doses, will provide better relief. After the first day, the total daily dose should generally not exceed 150 mg.

Pharmacological Actions: Antiplatelet actions are short-lasting- Neutrophil chemotaxis and superoxide production at the inflammatory site.

Diclofenac sodium is a phenylacetic acid derivative belonging to the carboxylic acid class of NSAIDs. It has been used successfully in the treatment of postoperative pain after oral surgery<sup>29</sup>. The anti-inflammatory property of diclofenac in lower third molar surgery was compared with methylprednisolone by Lopez et al who suggested that less inflammation was observed in Methylprednisolone group although there was no severe difference way in the reduction of trismus<sup>30</sup>. In another study intramuscular diclofenac sodium produced significant pain relief compared to tenoxicam<sup>18</sup>.

Bailey et al compared the analgesic efficacy and patient acceptability of soluble aspirin and Diclofenac dispersible in patients with postoperative pain after removal of impacted third molars and showed Diclofenac dispersible is superior to soluble aspirin in terms of pain relief and extent of mouth-opening achieved after extraction of impacted third molars<sup>31</sup>. It was shown by Chang et al that a single dose of rofecoxib 50 mg provided greater overall analgesic efficacy over 24 hours than with 3 doses of enteric-coated diclofenac sodium 50 mg<sup>32</sup>. In a single-blind, randomized study the analgesic efficacy and tolerability of a single dose of 100 mg Diclofenac potassium, 100 mg Diclofenac sodium softgel, and placebo for postoperative pain after third molar extraction were compared and concluded that softgel produced better pain relief. This could be attributed to the reason that the softgel gets rapidly absorbed and may positively affect the time of onset and duration of inflammatory<sup>10</sup>.

A prospective, randomized study comparing the effects of dexamethasone 8 mg IM and Diclofenac potassium 50 mg par oral (PO), dexamethasone 8 mg IM and acetaminophen 1000 mg PO, and monotherapy with Diclofenac K 50 mg PO on postoperative pain, swelling, and trismus after

surgical removal of third molars concluded concomitant treatment with dexamethasone and Diclofenac K provided significant relief<sup>33</sup>. Lima et al evaluated the analgesic efficacy of pre-operative and post-operative administration of aceclofenac in the control of pain after surgical extraction of impacted mandibular third molars and concluded that, Aceclofenac was more efficient in controlling pain when administered before the surgery<sup>34</sup>. Ketorolac: Ketorolac is a potent analgesic with modest anti-inflammatory activity.

Adverse Effects: Nausea, abdominal pain, dyspepsia, ulceration, loose stools, drowsiness, headache, dizziness, nervousness, pruritus.

In a randomized, double-blind, placebo-controlled study it was found that ketorolac and tramadol were equally effective in relieving post-operative pain following third molar surgery and pre-operative administration of ketorolac was better than its post-operative administration<sup>35</sup>. Grant et al evaluated the efficacy and safety of intranasal (IN) ketorolac in patients who had third molar extraction surgery with bony impactions and showed a single IN ketorolac 31.5 mg dose was well tolerated and provided rapid and effective pain relief in oral surgery patients for a period up to 8 hours<sup>14</sup>. Sublingual ketorolac has also been found to be effective for post-operative pain, trismus and swelling management in lower third molar surgery<sup>12</sup>.

Oxicam derivatives: Piroxicam is a Short-term analgesic and long-term anti-inflammatory.

Dosage: 20mg orally once a day or 10mg orally twice a day.

Adverse effects: Anorexia, heart burn, nausea

Pain, trismus and swelling following mandibular third molar surgery can be controlled by piroxicam administered orally or sublingually and there has been no significant difference between the two routes of administration of piroxicam<sup>11</sup>. Sublingual piroxicam has been equally effective to sublingual ketorolac in management of pain, swelling and trismus following lower third molar surgery<sup>12</sup>.

Meloxicam is a preferential COX-2 inhibitor. The analgesic and anti-inflammatory response of meloxicam was evaluated based on a dose dependent phenomenon after surgical extraction of lower third molars. The study concluded that pain, trismus and swelling after lower third molar removal not requiring osteotomy can be successfully controlled by a dose regimen of 7.5 mg meloxicam once daily. For more aggressive extractions 15 mg meloxicam is advisable<sup>36</sup>. It was shown in a study that patients who received meloxicam pre-operatively had less pain intensity than those receiving tramadol pre-operatively<sup>37</sup>.

Tenoxicam, a NSAID, is a thienothiazine derivative belonging to the oxicam group. Pharmacokinetic studies have shown that it is rapidly absorbed after oral administration, with a bioavailability of more than 99% and a plasma half-life of 72 hr<sup>38</sup>.

Nimesulides: Nimesulides are preferential COX-2 inhibitors.

Dosage: The usual dose is 100mg twice a day.

Children: 5mg/kg of body weight in 2 or 3 divided doses.

Adverse effects: Gastrointestinal- Abdominal discomfort, heartburn, abdominal cramps, nausea, vomiting and diarrhea.

Central Nervous System - Headache, dizziness and drowsiness.

Genitourinary - Blood in urine, decrease in urination and kidney failure.

In a double blind randomized study, the analgesic effectiveness and tolerability of oral treatment with once-daily nimesulide was compared with ibuprofen q6h over 24 hours in patients with postoperative pain associated with surgical extraction of an impacted third molar and the results suggested that the analgesic effect of nimesulide had a faster onset (<15 minutes) and was stronger than that of ibuprofen<sup>39</sup>. The efficacy of nimesulide and meloxicam in the control of pain, swelling and trismus, following the extraction of impacted inferior third molars was compared. In conclusion, pain control was similar in both treatment groups but nimesulide was more effective than meloxicam in the control of swelling and trismus following the extraction of impacted lower third molars<sup>40</sup>. Selective Cox-2 inhibitors Selective COX-2 inhibitors have the property of inhibiting COX-2 without affecting COX-1 function.

Concerns regarding selective COX-2 inhibitors

- These drugs do not have a wide range, as they do not control inflammation mediated by COX-1
- COX-2 inhibition can be injurious to gastric mucosa as they play a protective role by producing gastroprotective Prostaglandins
- COX-2 inhibition causes salt and water retention precipitating Congestive Heart Failure

The analgesic efficacy of preoperative rofecoxib, ibuprofen, and placebo in the control of postoperative pain after third molar surgery was compared in a clinical randomized, double-blind study and concluded that preoperative intake of rofecoxib provides a significantly better analgesic benefit than ibuprofen<sup>41</sup>. Daniels et al compared the efficacy of rofecoxib and valdecoxib in the treatment of acute postoperative dental pain. Rofecoxib had comparable analgesic efficacy to valdecoxib<sup>42</sup>. The analgesic efficacy and tolerability profile of rofecoxib with those of the centrally acting, nonsalicylate, opiate/nonopiate analgesic combination oxycodone/acetaminophen in patients with pain after dental surgery was studied and rofecoxib was found to be associated with a significantly lower incidence of nausea and vomiting compared with oxycodone/acetaminophen<sup>43</sup>.

Moore et al in a randomized prospective clinical trial compared the analgesic efficacy and the reduction in trismus of preoperative rofecoxib, intraoperative dexamethasone, and both rofecoxib and dexamethasone following third molar extraction surgery and showed that the combination of preoperative rofecoxib and intraoperative dexamethasone was most effective in minimizing pain and trismus following third molar surgery<sup>19</sup>. A systematic review of oral analgesics for third molar surgery showed that Ibuprofen, diclofenac and COX-2 inhibitors (valdecoxib and rofecoxib) offered distinct advantages over drugs such as aspirin, paracetamol and

dihydrocodeine. Furthermore, the superior efficacy of these compounds was also supported by a reduced risk of unwanted effects<sup>44</sup>.

The pre-operative administration of injectable Cyclooxygenase-2-Specific Inhibitor Parecoxib Sodium was found to be effective, safe, and well tolerated, providing significantly more analgesia<sup>45</sup>.

Oxaprozin: Oxaprozin is a long-acting non-steroidal anti-inflammatory drug. Its available as 600mg tablets and maximum recommended dose is 1800mg/day.

Kara et al studied the efficacy of oxaprozin in terms of their effects on edema, pain, and trismus after surgery for impacted mandibular third molars and showed that administration of either oxaprozin during the postoperative period is effective in reducing pain but questionable benefit for the management of trismus and edema<sup>46</sup>.

Lysine Clonixinate: Lysine Clonixinate is an analgesic that inhibits prostaglandin synthesis. Lysine Clonixinate showed a life span of 3 hours, and it is recognized as a non-steroid anti-inflammatory with the shortest life span when compared to other drugs of its category<sup>47,48</sup>.

The efficacy of Lysine Clonixinate, Dipyron and Paracetamol in controlling the postoperative pain in the surgery of inferior impacted third molars was assessed and it was found both lysine Clonixinate and dipyron were effective in pain control<sup>49</sup>.

Tramadol: Tramadol Hydrochloride is a centrally-acting synthetic analgesic of the aminocyclohexanol group with opioid-like effects

Dosage: Most people are recommended to start with a low dosage of tramadol, such as 25 mg (half a tablet) once daily in the morning. The usual dose is 50 to 100 mg every four to six hours as needed for pain, up to a maximum of 400 mg total per day.

Pharmacological actions

- Inhibits reuptake of Na and 5-HT and activates monoaminergic spinal inhibition of pain.
- Analgesic
- Preanaesthetic medication
- Balanced anaesthesia and surgical anaesthesia
- Relief of anxiety and apprehension

The possible mechanism by which this drug brings about pain relief as effective as NSAIDs is an interesting factor which warrants discussion. Opening of potassium channels located in the primary afferent nerve endings produces anti-nociception and represents an important step in the peripheral anti-nociceptive effect of several NSAIDs. Activation of the NO-cyclic guanosine monophosphate (GMP) pathway could also induce anti-nociception through the opening of potassium channels.

Tramadol Hydrochloride is contraindicated in:

- Individuals with known hypersensitivity to Tramadol Hydrochloride or any excipients
- Acute intoxication with alcohol, hypnotics, analgesics, opioids or psychotropic drugs
- Patients who are taking MAO inhibitors or who have taken them within the last 14 days
- known hypersensitivity to opioids
- Patients with uncontrolled epilepsy or epilepsy not adequately controlled by treatment.

Jung et al compared the onset of analgesia and other measures of analgesic efficacy of a combination of Tramadol Hydrochloride and acetaminophen and other strong combination analgesics for the management of acute pain. The study concluded that the combination of Tramadol Hydrochloride and acetaminophen provided rapid and effective analgesia for acute postoperative dental pain<sup>50</sup>.

Studies have reported that intra-muscular (IM) administration of tramadol pre-emptively offered better pain relief than post-operative administration via the same route<sup>8</sup>. It has also been shown that intra-venous (IV) tramadol provides better pain relief than oral tramadol. But administration of tramadol via the IM or IV routes could result in side effects like depression and sedation<sup>13</sup>. In a study of the effects of Tramadol Hydrochloride on dentoalveolar surgical pain by Collins et al, 39% of patients on high doses of Tramadol Hydrochloride (100 mg 4 times a day orally), 12% on moderate doses (50 mg 4 times a day), and 6% on low dose (50 mg 2 times a day) withdrew from the study owing to nausea, vomiting, dizziness, or drowsiness<sup>51</sup>.

**Ketamine:** Ketamine is an anesthetic agent which acts on the central nervous system and produces dissociative anesthesia. It has been found to produce profound analgesia.

Local anesthetic combined with sub-anesthetic ketamine for the relief or prevention of postoperative pain, swelling, and trismus after the surgical extraction of third molars was studied and it showed that this combination produced good local anesthesia while affording a comfortable procedure for the surgeon and patient and providing good postoperative analgesia with less swelling and significantly less trismus<sup>52</sup>. The clinical efficacy of midazolam plus low-dose ketamine conscious intravenous sedation on relief from or prevention of postoperative pain, swelling, and trismus after the surgical extraction of third molars was analysed and concluded that intravenous low-dose ketamine may be safe and effective in reducing postoperative pain<sup>53</sup>.

**Narcotics:** Narcotic agents are at some hospitals the standard for relief of postoperative pain, but these drugs are often inappropriate for use in day-case hospitals since, they can cause respiratory depression, nausea.

Dexmedetomidine is an alpha 2-adrenoreceptor agonist, which provides sedation, analgesia, and anxiolysis in clinical practice<sup>54</sup>. Activation of central alpha 2-adrenoreceptors in the locus ceruleus<sup>2</sup> is responsible for both analgesic and sedative effects<sup>55</sup>. In a study by Cheung et al it was found that intranasal Dexmedetomidine produced improved postoperative analgesia for unilateral third molar surgery under local anaesthesia and there was no increase in complications or delay in psychomotor recovery<sup>15</sup>.

## CONCLUSION

The pain and discomfort associated with third molar surgery is as a result of inflammatory sequelae and therefore, non-steroidal anti-inflammatory drugs remain the first choice of analgesics. For whom non-steroidal anti-

inflammatory drugs are contraindicated, synthetic opioids such as tramadol has been found as effective alternative. These drugs produce significant pain relief and improve the quality of patient's life in the immediate post-operative period.

## REFERENCES

1. Barden J, Edwards JE, McQuay HJ, Moore RA. Pain and analgesic response after third molar extraction and other postsurgical pain. *Pain* 2004;107:86-90
2. Cooper SA, Precheur H, Rauch D, Rosenheck A, Ladov M, Engel J. Evaluation of oxycodone and acetaminophen in treatment of postoperative pain. *Oral Surg Oral Med Oral Pathol* 1980; 50:496-501.
3. Seymour RA, Blair GS, Wyatt FAR: Postoperative dental pain and analgesic efficacy, part II. Analgesic usage and efficacy after dental surgery. *Br J Oral Surg* 1983; 21:298-303
4. Olmedo-Gaya MV, Vallecillo-Capilla M, Galvez-Mateos R. Relation of patient and surgical variables to postoperative pain and inflammation in the extraction of third molars. *Med Oral*. 2002;7:360-9
5. Ong KS, Seymour RA, Chen FG, Ho VCL. Preoperative ketorolac has a preemptive effect for postoperative third molar surgical pain. *Int J Oral Maxillofac* 2004; 33: 771-776.
6. Campbell WI, Kendrick RW, Fee JPH. Balanced preemptive analgesia: does it work? A double-blind, controlled study in bilaterally symmetrical oral surgery. *Br J Anaesth* 1998; 81: 727-730.
7. Lebrun T, Van Elstraete AC, Sandefo I, Polin B, Pierre-Louis L. Lack of pre-emptive effect of low-dose ketamine on postoperative pain following oral surgery. *Can J Anesth* 2006; 53: 146-152.
8. Pozos-Guillen A, Martinez-Rider R, Aguirre-Banuelo, Perez-Urizar J.: Pre-Emptive Analgesic Effect of Tramadol Hydrochloride After Mandibular Third Molar Extraction: A Pilot Study. *J Oral Maxillofac Surg* 2007; 65:1315-1320.
9. Helmy SA, Bali A. The effect of the pre-emptive use of the NMDA receptor antagonist dextromethorphan on postoperative analgesic requirements. *Anesth Analg* 2001; 92: 739-74.
10. Zuniga JR, PhD, Phillips CL, Shugars D, Lyon JA, Peroutka SJ, Swarbrick J, Bon C.: Analgesic Safety and Efficacy of Diclofenac Sodium Softgels on Postoperative Third Molar Extraction Pain. *J Oral Maxillofac Surg* 2004; 62:806-815.
11. Trindade PAK, Giglio FPM, Colombini-Ishikiriama BL, Calvo AM, Modena KC, Ribeiro DA et al. Comparison of oral versus sublingual piroxicam during postoperative pain management after lower third molar extraction. *Int. J. Oral Maxillofac. Surg.* 2011; 40: 292-297
12. Trindade PA, Giglio FP, Colombini-Ishikiriama BL, Calvo AM, Modena KC, Ribeiro DA, Dionísio TJ, Brozoski DT, Lauris JR, Faria FA, Santos CF. Sublingual ketorolac and sublingual piroxicam are equally effective for postoperative pain, trismus, and swelling management in lower third molar removal.

- Oral Surg Oral Med Oral Pathol Oral Radiol. 2012 Jul; 114(1):27-34.
13. Ong CK, Lirk P, Tan JM, Sow BW. The analgesic efficacy of intravenous versus oral Tramadol Hydrochloride for preventing postoperative pain after third molar surgery. *J Oral Maxillofac Surg* 2005; 63:1162-8.
  14. Grant GM, Mehlisch DR. Intranasal ketorolac for pain secondary to third molar impaction surgery: a randomized, double-blind, placebo-controlled trial. *J Oral Maxillofac Surg*. 2010 May; 68(5):1025-31.
  15. Cheung CW, Ng KF, Liu J, Yuen MY, Ho MH, Irwin MG. Analgesic and sedative effects of intranasal dexmedetomidine in third molar surgery under local anaesthesia. *British Journal of Anaesthesia* 2011;107(3): 430-7
  16. Talgaonkar S, Mishra PR. Intranasal delivery: an approach to bypass the blood brain barrier. *India J Pharmacol* 2004; 36: 140-7
  17. Turker S, Onur E, Ozer Y. Nasal route and drug delivery systems. *Pharm World Sci* 2004; 26: 137-42.
  18. Roelofse JA, Van der Bijl P, Joubert JJ. Analgesic and anti-inflammatory efficacy of tenoxicam and diclofenac sodium after third molar surgery. *Anesth Prog*. 1996 Fall; 43(4):103-7.
  19. Moore PA, Brar P, Smiga ER, Costello BJ: Preemptive rofecoxib and dexamethasone for prevention of pain and trismus following third molar surgery. *Oral Surg Oral Med Oral Pathol Radiol Endod* 2005, 99:E1-7.
  20. Jackson DL, Moore PA, Hargreaves KM: Preoperative non-steroidal anti-inflammatory medication for the prevention of postoperative dental pain. *JADA* 1989, 119:641-647.
  21. Van der Westhuijzen AJ, Roelofse JA, Grotepass FW, Becker PJ. Randomized double-blind comparison of tiaprofenic acid and diclofenac sodium after third molar surgery. *Oral Surg Oral Med Oral Pathol* 1994, 78:557-566.
  22. Isakson P, Hubbard R.: Analgesics - nonsteroidal anti-inflammatory drugs. In: Evers AS, Maze M (editors). *Anesthetic pharmacology: physiologic principles and clinical practice*. Livingstone (PA): Churchill; 2004. p. 435-55
  23. Desjardins PJ, Hersh EV, Trummel CL, Cooper SA. Nonopioid Analgesics, Nonsteroidal antiinflammatory drugs, and antirheumatic and antigout drugs. In: Yagiela JA (editor). *Pharmacology and therapeutics for dentistry*, 5th ed. St. Louis (MO): Mosby; 2004. p. 331-64
  24. Bannwarth B. Comparative safety of traditional non-steroidal anti-inflammatory drugs and COX-2 selective inhibitors. *Presse Med* 2002; 31(39 Pt 2):7-9.
  25. Moore RA, Straube S, Paine J, Derry S, McQuay HJ: Minimum efficacy criteria for comparisons between treatments using individual patient meta-analysis of acute pain trials: Examples of etoricoxib, paracetamol, ibuprofen, and ibuprofen/paracetamol combinations after third molar extraction. *PAIN* 2011;152(5):982-989.
  26. Ziccardi VB, Desjardins PJ, Daly-DeJoy E, Seng GF. Single-Dose Vicoprofen Compared with Acetaminophen With Codeine and Placebo in Patients with Acute Postoperative Pain After Third Molar Extractions. *J Oral Maxillofac surg* 2000; 58: 622-628.
  27. Joshi A, Snowdon AT, Rood JP, Worthington HV. Pain control after routine dento-alveolar day surgery: a patient satisfaction survey. *Br Dent J*. 2000 Oct 28; 189(8):439-42.
  28. Kaczmarzyk T, Wichlinski J, Stypulkowska J, Zaleska M, Woron J.: Preemptive effect of ketoprofen on postoperative pain following third molar surgery. A prospective, randomized, double-blinded clinical trial. *Int. J. Oral Maxillofac. Surg*. 2010; 39: 647-652.
  29. Matthews RW, Scully CM, Levers BGH: The efficacy of diclophenac sodium with and without paracetamol in the control of post-surgical dental pain. *Br Dent J* 1984; 157:357-359.
  30. López Carriches C, Martínez González JM, Donado Rodríguez M. The use of methylprednisolone versus diclofenac in the treatment of inflammation and trismus after surgical removal of lower third molars *Med Oral Patol Oral Cir Bucal* 2006; 11:E440-5.
  31. Bailey BMW, Zaki G, Rotman H, Woodward RT." A double-blind comparative study of soluble aspirin and diclofenac dispersible in the control of postextraction pain after removal of impacted third molars. *Int. J. Oral Maxillofac. Surg*. 1993; 22." 238-241
  32. Chang DJ, Desjardins PJ, Chen E Polis AB, McAvoy M, Mockoviak SH, Geba GP.: Comparison of the Analgesic Efficacy of Rofecoxib and Enteric-Coated Diclofenac Sodium in the Treatment of Postoperative Dental Pain: A Randomized, Placebo-Controlled Clinical Trial. *Clinical Therapeutics* 2002; 24(4):490-503.
  33. Bamgbose BO, Akinwande JA, Adeyemo WL: A prospective, randomized, open label, pilot clinical trial comparing the effects of dexamethasone coadministered with Diclofenac potassium or acetaminophen and Diclofenac potassium monotherapy after third molar extraction in adults. *Current therapeutic research*. 2006;67:230-240
  34. Presser Lima PV, Fontanella V.: Analgesic efficacy of aceclofenac after surgical extraction of impacted lower third molars. *Int. J. Oral Maxillofac. Surg*. 2006; 35: 518-521.
  35. Mishra H, Khan FA. A double-blind, placebo-controlled randomized comparison of pre and postoperative administration of ketorolac and tramadol for dental extraction pain. *J Anaesthesiol Clin Pharmacol*. 2012 Apr; 28(2):221-5.
  36. Calvo AM, Sakai VT, Giglio FPM, Modena KC, Colombini BL, Benetello V, et al: Analgesic and anti-inflammatory dose response relationship of 7.5 and 15 mg meloxicam after lower third molar removal: a double-blind, randomized, crossover study. *Int. J. Oral Maxillofac. Surg*. 2007; 36: 26-31.

37. Isiordia-Espinoza MA, Sánchez-Prieto M, Tobías-Azúa F, Reyes-García JG Pre-emptive analgesic effectiveness of meloxicam versus tramadol after mandibular third molar surgery: a pilot study. *J Oral Maxillofac Surg.* 2012 Jan; 70(1):31-6.
38. Heintz RD, Guentert TW, Enrico JF, Dubach UC, Brandt R, Jeunet FS.: Pharmacokinetics of tenoxicam in healthy human volunteers. *Eur J Rheum Inflamm* 1984; 7:33-44.
39. Bocanegra M, Seijas A, Yibirin MG. Nimesulide Versus Ibuprofen in Pain Management After Surgical Extraction of an Impacted Third Molar: A 24-Hour, Double-Blind, Randomized, Double-Dummy, Parallel-Group Study. *Current therapeutic research* 2005; 66(3):172-180.
40. De Menezes SAF, Cury PR: Efficacy of nimesulide versus meloxicam in the control of pain, swelling and trismus following extraction of impacted lower third molar. *Int. J. Oral Maxillofac. Surg.* 2010; 39: 580–584
41. Chiu WK, Cheung LK: Efficacy of preoperative oral rofecoxib in pain control for third molar surgery. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2005;99:E47-53
42. Daniels SE, Desjardins PJ, Talwalker S, Recker DP, Verburg KM. The analgesic efficacy of valdecoxib vs. oxycodone/acetaminophen after oral surgery. *J Am Dent Assoc* 2002; 133: 611– 621
43. Korn S, Vassil TC, Kotey PN, Fricke JR Jr: Comparison of Rofecoxib and Oxycodone Plus Acetaminophen in the Treatment of Acute Pain: A Randomized, Double-Blind, Placebo-Controlled Study in Patients with Moderate to Severe Postoperative Pain in the Third Molar Extraction Model. *Clinical Therapeutics* 2004; 26(5):769-778.
44. J. Barden, Edwards JE, McQuay HJ, Wiffen PJ, Moore RA. Oral analgesics after third molar surgery - a systematic review of relative efficacy of oral analgesics after third molar extraction *Br Dent J* 2004; 197: 407-411
45. Desjardins PJ, Grossman EH, Kuss ME, Talwalker S, Dhadda S, Baum D, Hubbard RC. The injectable cyclooxygenase-2-specific inhibitor parecoxib sodium has analgesic efficacy when administered preoperatively. *Anesth Analg.* 2001 Sep; 93(3):721-7.
46. Kara SM, Polat S, Inci MF, Gümü C. : Analgesic and Anti-Inflammatory Effects of Oxaprozin and Naproxen Sodium After Removal of Impacted Lower Third Molars: A Randomized, Double-Blind, Placebo-Controlled Crossover Study: *J Oral Maxillofac Surg* 2010; 68:1018-1024.
47. Martí ML, De los Santos AR, Di Girolamo G, Gil M, Manero EO, Fraga C. Lysine clonixinate in minor dental surgery: double-blind randomized parallel study versus paracetamol. *Int J Tissue React.*1993; 15:207-13.
48. González-Martin G, Cattán C, Zuñiga S. Pharmacokinetics of lysine clonixinate in children in postoperative care. *Int J Clin Pharmacol Ther.* 1996;34:396-9
49. Noronha VR, Gurgel GD, Alves LC, Noman-Ferreira LC, Mendonça LL, Aguiar EG, Abdo EN. Analgesic efficacy of Lysine Clonixinate, paracetamol and dipyrone in lower third molar extraction. A randomized controlled trial. *Med Oral Patol Oral Cir Bucal* 2009 Aug 1;14 (8):e411-5.
50. Jung YS, Kim DK, Kim MK: Onset of Analgesia and Analgesic Efficacy of Tramadol Hydrochloride/Acetaminophen and Codeine/Acetaminophen/Ibuprofen in Acute Postoperative Pain: A Single-Center, Single-Dose, Randomized, Active-Controlled, Parallel-Group Study in a Dental Surgery Pain Model. *Clinical Therapeutics* 2004; 26:7:1037-45.
51. Collins M, Young I, Sweeney P, Fenn GC, Stratford ME, Wilson A et al. The effect of tramadol on dento-alveolar surgical pain. *Br J Oral Maxillofac Surg.* 1997 Feb; 35(1):54-8.
52. Satilmis T, Garip H, Arpacı E, Sener C, Göker K.: Assessment of Combined Local Anesthesia and Ketamine for Pain, Swelling, and Trismus After Surgical Extraction of Third Molars. *J Oral Maxillofac Surg* 2009; 67:1206-1210.
53. Garip H, Satilmis T, Dergin G. Effects of Midazolam/Low-Dose Ketamine Conscious Intravenous Sedation on Pain, Swelling, and Trismus After Surgical Extraction of Third Molars. *J Oral Maxillofac Surg* 2011; 69:1023-1030.
54. Hall JE, Uhrich TD, Barney JA, Arain SR, Ebert TJ. Sedative, amnestic, and analgesic properties of small-dose dexmedetomidine infusions. *Anesth Analg* 2000; 90: 699–705
55. Correa-Sales C, Rabin BC, Maze M. A hypnotic response to dexmedetomidine, an alpha 2 agonist, is mediated in the locus coeruleus in rats. *Anesthesiology* 1992; 76: 948–52